Adicet Bio, Inc. (FRA:1IJA)

Germany flag Germany · Delayed Price · Currency is EUR
0.411
-0.020 (-4.69%)
At close: Dec 4, 2025
-59.00%
Market Cap 76.96M
Revenue (ttm) n/a
Net Income (ttm) -98.03M
Shares Out n/a
EPS (ttm) -1.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 970
Open 0.411
Previous Close 0.431
Day's Range 0.411 - 0.411
52-Week Range 0.336 - 1.104
Beta n/a
RSI 37.79
Earnings Date Mar 6, 2026

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company’s lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodg... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 152
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 1IJA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.